Selank: Calm Without Sedation, Evidence From One Region

The short version

Selank is a synthetic heptapeptide — seven amino acids — with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed by adding a three-amino-acid tail (Pro-Gly-Pro) to an endogenous immunomodulatory peptide called tuftsin, which normally floats free in the immune system as a fragment of the IgG heavy chain. The tail's job is stability: it slows enzymatic breakdown, giving the peptide more time to act.

In animal models and a limited body of Russian clinical studies, Selank shows anxiolytic — anxiety-reducing — effects without the sedation, muscle relaxation, or dependence risk of benzodiazepines ^[8]. It also modulates immune signaling, which sets it apart from classical anxiolytics ^[12]. As of 2026, Selank is registered as a prescription anxiolytic in Russia; it is not approved by the FDA or EMA for any indication; and outside Russia it is sold strictly as a research chemical. This page summarizes the evidence; it does not recommend Selank and lists no human dose.

What it is

Selank is a synthetic peptide analog of tuftsin (Thr-Lys-Pro-Arg), the endogenous tetrapeptide that is an IgG-derived immunomodulator. Its full sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro; the C-terminal extension Pro-Gly-Pro protects it from the peptidases (protein-scissors) that would rapidly break down native tuftsin. It is also referred to in older literature as TP-7 and Heptapeptide Selank.

This tuftsin ancestry means Selank carries an immunomodulatory profile alongside its neurological ones — it modulates cytokine balance and immune-cell signaling in ways that most anxiolytics do not ^[12]. The distinction matters both mechanistically and for safety: it is not simply a GABA drug.

How it works

Selank's anxiolytic and nootropic effects are attributed to two overlapping, non-benzodiazepine mechanisms.

GABAergic modulation. A 2018 review of Selank's molecular pharmacology established that it acts as a positive allosteric modulator of GABA receptor binding — meaning it makes the receptor more responsive to the brain's own calming neurotransmitter, GABA, without occupying the same binding site as benzodiazepines. The modulation is subtype-selective and concentration-dependent, and Selank can also block the modulatory activity of diazepam and olanzapine at the same receptor, indicating distinct but overlapping sites ^[8]. A 2016 gene-expression study in rat frontal cortex found that Selank changed the expression of 45 GABA-pathway genes after one hour, with the shifts correlating positively with those produced by GABA itself ^[10].

Enkephalin stabilization. Selank also inhibits enkephalin-degrading enzymes (enkephalinases), which stabilizes the brain's own endogenous opioid-like peptides (enkephalins). This engages the opioid/anti-anxiety system without acting as an exogenous opioid. The combination of a GABAergic and an enkephalin-sparing mechanism is one reason Selank's anxiolytic profile is described as qualitatively different from benzodiazepines.

Neurotrophic signaling. Intranasal Selank upregulated BDNF expression in the rat hippocampus in vivo ^[11]. BDNF (brain-derived neurotrophic factor) is a protein that supports neuron survival and plasticity, which links Selank to the nootropic effects — improved stress resilience and memory consolidation — that appear alongside its anxiolytic action.

Immunomodulation. In patients with anxiety-asthenic disorders, Selank shifted the Th1/Th2 cytokine balance and modulated IL-6 expression in peripheral blood ^[12]. This establishes a distinct immunomodulatory action that runs parallel to its neurological ones and that has no counterpart in benzodiazepines.

What the research shows

GABA receptor pharmacology. The 2018 review by Vyunova et al. is the primary mechanistic reference. It establishes Selank as a positive allosteric modulator of GABA receptor binding with subtype-selective, concentration-dependent activity, distinguishing it from the benzodiazepine binding site while showing overlapping functional consequences ^[8].

Chronic stress model. In rats exposed to unpredictable chronic mild stress (UCMS), the combination of diazepam with Selank was the most effective intervention for reducing anxiety, restoring behavior toward pre-stress levels ^[9]. The synergistic result supports — and simultaneously complicates — GABAergic interaction: the two drugs together do more than either alone.

Gene expression in frontal cortex. In rat frontal cortex, Selank administration changed the expression of 45 genes involved in GABAergic neurotransmission at one hour and 22 genes at three hours, with changes correlating positively with those produced by GABA itself ^[10].

BDNF regulation. Intranasal Selank regulated (increased) BDNF expression in the rat hippocampus in vivo ^[11], linking the peptide to neuroplasticity-related effects relevant to its reported nootropic profile.

Immune axis in humans. In a human study of patients with anxiety-asthenic disorders, Selank altered the Th1/Th2 cytokine balance in serum and modulated IL-6 expression in peripheral blood cells, characterizing it as a novel immunomodulator alongside its anxiolytic action ^[12]. This is the only finding listed here with human subjects; the clinical context is supervised, diagnosed patient care, not unsupervised self-experimentation.

Reported effects, cautions & safety

Nootropic and peptide communities produce some of the most consistent and detailed self-experimentation reports for Selank of any compound in this category. The following are anecdotal, not clinical evidence, and are reproduced because they are informative about how the compound is actually experienced.

What users commonly report: The single most consistent description is a softening of background anxiety that does not feel like sedation — the "edge taken off" while mental clarity holds. Frequently contrasted explicitly with the heavy fogginess of benzodiazepines and the emotional flatness of SSRIs. People use it situationally ahead of presentations, exams, and difficult conversations and report markedly less anticipatory anxiety. Fast onset intranasally — typically within 20 to 40 minutes — makes it suited to situational use. A recurring theme of "calm but sharp" rather than numbed. Over one to two weeks of regular use, many describe a gradual mood lift and greater stress resilience. A minority, particularly with higher or more frequent use, report feeling slightly too calm, mildly drowsy, or mentally soft.

Nasal irritation (dryness, burning, stinging, sneezing) is the most commonly reported tolerability issue with the intranasal route and is usually attributed to the carrier rather than the peptide. Occasional headache is reported at higher use. No dependence, rebound anxiety, or withdrawal is commonly reported — though this rests on short-term and anecdotal experience, not long human safety trials.

Cited cautions from the literature:

• Unregulated research-chemical sourcing. Outside Russia, Selank is sold as a research chemical with no pharmaceutical-grade guarantee of purity, identity, or sterility ^[8].
• Long-term safety not established. Human data are confined to small Russian clinical studies over courses of weeks; there is no large, long-duration safety follow-up and no Western replication at scale ^[8].
• Multi-system interaction risk. Selank touches GABAergic, opioid, monoaminergic, and immune pathways. Interactions with medications across those systems — sedatives, opioids, SSRIs, immune-modulating drugs — are essentially unstudied in people ^{[8][9][10][12]}.
• Immune-signaling unknowns. As a tuftsin analog, Selank modulates cytokine balance. Consequences in people with autoimmune conditions, active infection, or immune-modulating medications are not characterized ^[12].
• Self-treatment delays real care. Persistent or impairing anxiety is a medical condition with established, evidence-based treatments. Selank is not a substitute for professional evaluation ^[8].
• Not FDA-approved; not for human consumption. Outside Russia, Selank has no approved clinical use and is sold for research purposes only ^[8].

Where it fits in sleep and recovery research

Selank occupies the anxiety-quieting corner of this desk. It is not a sleep peptide in the same direct sense that DSIP is named to be — its mechanism runs through anxiolytic signaling, and any sleep benefit appears to be secondary to reduced anxious arousal. That distinction is actually meaningful: many people have trouble sleeping because of racing, anxious thoughts, and a compound that quiets that without sedating may produce better sleep architecture than one that simply forces drowsiness.

Its mechanistic story is also considerably better worked out than DSIP's — two identified pathways (GABAergic allosteric modulation and enkephalinase inhibition), gene-expression data, and a BDNF link — even if the clinical record is geographically narrow. Where DSIP is the most honest illustration of an unresolved endogenous sleep signal, Selank is the more mechanistically characterized compound with a broader and more consistent community profile. Neither is fully validated for human therapeutic use. See the comparison page for how they line up.